Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer.

Authors:
Li J; Cao Y; Liu Y; Yu L; Zhang Z and 12 more

Journal:
J Immunother Cancer

Publication Year: 2024

DOI:
10.1136/jitc-2023-008355

PMCID:
PMC10806547

PMID:
38199610

Journal Information

Full Title: J Immunother Cancer

Abbreviation: J Immunother Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Therapeutics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the scrna-seq data are available in ncbi-geo at https://www ncbi nlm nih gov/geo/ reference numbers gse128223 and gse190075. t cells have a heterogeneous infiltration level in cervical cancer tissues and that their infiltration level was positively correlated with the prognosis of patients10 1136/jitc-2023-008355 supp4 supplementary data 10 1136/jitc-2023-008355 supp5 supplementary data 10 1136/jitc-2023-008355 supp1 supplementary data in the above analysis we found that clinical characteristics were not determinants of the level of ??; t-cell infiltration levels10 1136/jitc-2023-008355 supp6 supplementary data 10 1136/jitc-2023-008355 supp7 supplementary data figure 3 the focal somatic mutations and tumor microenvironment characteristics of cervical carcinoma tissue were associated with the infiltration level of ??; t cells were identified from scrna-seq data of cervical carcinoma tissues and studies on their function in the tme can follow 10 1136/jitc-2023-008355 supp9 supplementary data 10 1136/jitc-2023-008355 supp10 supplementary data figure 4 chasing down ??"

Code Sharing
Evidence found in paper:

"Competing interests: None declared."

Evidence found in paper:

"Funding: This work was supported by the National Natural Science Foundation of China under Grant 82172674; Cancer Precision Radiotherapy Spark Program of China International Medical Foundation under Grant 2019-N-11-26; Tianjin Key Medical Discipline (Specialty) Construction Project under Grant TJYXZDXK-009A; Construction Project of Cancer Precision Diagnosis and Drug Treatment Technology (TMUCIH) under Grant ZLJZZDYYWZL08; Clinical Trial Project (TMUCIH) under Grant TZ3582022-005 and TZ3582022-011; and Wu Jieping Medical Foundation under Grant 320.6750.2020-10-96."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025